{"organizations": [], "uuid": "031828d75046c45c1a38c4df36d5a92a2aefb005", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180227.html", "section_title": "Archive News &amp; Video for Tuesday, 27 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-gilead-natco-and-teva-requested-fd/brief-gilead-natco-and-teva-requested-fda-permission-to-make-generic-version-of-sovaldi-sec-filing-idUSFWN1QH0QD", "country": "US", "domain_rank": 408, "title": "BRIEF-Gilead: Natco And Teva Requested FDA Permission To Make Generic Version Of Sovaldi - SEC Filing", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-27T19:44:00.000+02:00", "replies_count": 0, "uuid": "031828d75046c45c1a38c4df36d5a92a2aefb005"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-gilead-natco-and-teva-requested-fd/brief-gilead-natco-and-teva-requested-fda-permission-to-make-generic-version-of-sovaldi-sec-filing-idUSFWN1QH0QD", "ord_in_thread": 0, "title": "BRIEF-Gilead: Natco And Teva Requested FDA Permission To Make Generic Version Of Sovaldi - SEC Filing", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "sec", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "natco", "sentiment": "negative"}, {"name": "gilead sciences inc", "sentiment": "negative"}, {"name": "natco pharma", "sentiment": "none"}, {"name": "teva pharma", "sentiment": "none"}, {"name": "anda", "sentiment": "none"}, {"name": "teva", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gilead", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 27 (Reuters) - Gilead Sciences Inc:\n* GILEAD SCIENCES INC SAYS IN FEBRUARY 2018, CO RECEIVED NOTICES FROM NATCO PHARMA LIMITED AND TEVA PHARMA - SEC FILING\n* GILEAD SCIENCES INC - NATCO PHARMA LIMITED,TEVA EACH SUBMITTED ANDA TO FDA REQUESTING PERMISSION TO MANUFACTURE AND MARKET GENERIC VERSION OF SOVALDI\n* GILEAD SCIENCES - TEVA ALLEGES THAT NINE PATENTS ASSOCIATED WITH SOFOSBUVIR INVALID, UNENFORCEABLE AND/OR WILL NOT BE INFRINGED BY TEVA’S MANUFACTURE\n* GILEAD SCIENCES-NATCO PHARMA ALLEGES THAT TWO PATENTS ASSOCIATED WITH SOFOSBUVIR INVALID,UNENFORCEABLE AND/OR WILL NOT BE INFRINGED BY NATCO’S MANUFACTURE Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-27T19:44:00.000+02:00", "crawled": "2018-02-28T12:47:21.028+02:00", "highlightTitle": ""}